Group 1 - The core viewpoint of the article highlights the progress of WuXi AppTec's CAR-T cell therapy, Rukiyou Lunsai injection, in negotiations for inclusion in the commercial health insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] - This therapy is noted as the first domestically approved Class 1 CAR-T product in China, with a listed price of 1.29 million yuan per injection [1]